loading page

Melatonin-Based Therapeutics for Atherosclerotic Lesions and Beyond: Focusing on Macrophage Mitophagy
  • +5
  • Amir Ajoolabady,
  • David McClements,
  • Yaguang Bi,
  • Gregory Y.H. Lip,
  • Des Richardson,
  • Daniel Klionsky,
  • Russ Reiter,
  • Jun Ren
Amir Ajoolabady
University of Wyoming
Author Profile
David McClements
University of Massachusetts Amherst
Author Profile
Yaguang Bi
Zhongshan Hospital Fudan University
Author Profile
Gregory Y.H. Lip
University of Liverpool
Author Profile
Des Richardson
University of sydney
Author Profile
Daniel Klionsky
University of Michigan
Author Profile
Russ Reiter
University of Texas Health Science Center
Author Profile
Jun Ren
University of Wyoming College of Health Sciences

Corresponding Author:[email protected]

Author Profile

Abstract

Atherosclerosis refers to a unique form of chronic inflammatory anomaly of the vasculature, presented as rupture-prone or occlusive lesions in arteries. In advanced stages, atherosclerosis leads to the onset and development of multiple cardiovascular diseases with lethal consequences. Inflammatory cytokines in atherosclerotic lesions contribute to the exacerbation of atherosclerosis. Pharmacotherapies targeting dyslipidemia, hypercholesterolemia and neutralizing inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-17, and IL-12/23) have displayed some promising although contradictory results. Moreover, adjuvants such as melatonin, a pluripotent agent with proven anti-inflammatory, anti-oxidative and neuroprotective properties, also display promises in alleviating cytokine secretion in macrophages through mitophagy activation. Here, we share our perspectives on this concept and present melatonin-based therapeutics as a means to modulate mitophagy in macrophages and, thereby, ameliorate atherosclerosis.